Neuromedin U (Human)

Neuromedin U (Human)

Neuromedin U (NMU) is a multifunctional neuropeptide involved in regulating immune responses, inflammation, energy homeostasis, and smooth muscle contraction. This 25-residue human peptide is known for its potent activation of NMU receptors, influencing type 2 innate lymphoid cell (ILC2) responses and modulating cytokine production at mucosal barrier sites.

Researchers use Neuromedin U to study neuroimmune signaling, platelet activation, metabolic disorders, and receptor-ligand interactions. It has been shown to enhance ADP- and epinephrine-induced platelet aggregation, promote type 2 inflammation, and regulate ILC2 activity in barrier tissues. Structural studies have revealed key insights into its receptor selectivity and activation mechanisms, making it a valuable tool in immunology, endocrinology, and peptide pharmacology.

This product is supplied as a highly pure aqueous solution and is ideal for in vitro assays, receptor binding studies, and functional characterization of NMU pathways. It is intended for Research Use Only (RUO) and not for diagnostic or therapeutic applications.

Key Features:

• Human Neuromedin U-25 peptide in aqueous solution
• Validated for use in neuroimmune and inflammatory signaling studies
• Molar Mass: 3080.4 g/mol; Storage: 20C
• RUO designation: not for clinical or therapeutic applications

WARNING:
This product is for Research Use Only (RUO). It is not intended for human or animal use, diagnostic procedures, or therapeutic applications.

References:
1: Ye Y et al. Neuromedin U promotes human type 2 immune responses Mucosal Immunol. 2022 May;15(5):990-999.
2: De Prins A et al. Neuromedin U and Structural Analogs: Overview Curr Med Chem. 2020;27(39):6744-6768.
3: Tsou AM et al. Neuropeptide regulation of ILC2 responses Nature. 2022 Nov;611(7937):787-793.
4: Grippi C et al. Neuromedin U potentiates platelet activation Thromb Res. 2017 Nov;159:100-108.
5: Ye Y et al. Neuromedin U: roles in immunity and inflammation Immunology. 2021 Jan;162(1):17-29.
6: You C et al. Structural insights into NMU receptor activation Nat Commun. 2022 Apr 19;13(1):2045.
7: Teranishi H, Hanada R. Neuromedin U in metabolic disorders Int J Mol Sci. 2021 Apr 19;22(8):4238.
8: Nagashima H et al. CGRP limits ILC2 responses Immunity. 2019 Oct 15;51(4):682-695.e6.
9: Kuhre RE et al. Neuromedin U does not act as a decretin in rats Cell Metab. 2019 Mar 5;29(3):719-726.e5.
10: Martinez VG, ODriscoll L. Neuromedin U: pleiotropic roles Clin Chem. 2015 Mar;61(3):471-82.